
Renascience
4889.TRenascience Inc. Price (4889.T)
Stock Price
Market Cap
Fetching Data...
Enterprise Value
Fetching Data...
Volume
Fetching Data...
Shares Outstanding
12,711,700
(0)%Description
Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of pre... Read More
Sector: Healthcare
- Previous Close Fetching Data...
- Range $263-2474
- Market Cap 12.36B
- Enterprise Value No Data
- Avg Volume Fetching Data...
- P/E Ratio Fetching Data...
- Dividend Yield Fetching Data...
Industry: Biotechnology
- ceo: Keisuke Furuta
- IPO Date: September, 24, 2021
- Country: JP
- Currency: JPY
- Headquaters: No Data
- Employees: 4
- Revenue from each product or segment:
Product or Segment | Value: | % - Total | Last 3Y: |
---|

- Revenue by Region
Product or Segment | Value: | % - Total | Last 3Y: |
---|
